$TER

Smith Gregory Stephen sold $1.4M of TER

Smith Gregory Stephen (President and CEO) sold 4,000 shares of TERADYNE, INC (TER) at $356.31 ($1.43M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Smith Gregory Stephen
Published Jul 16, 2026, 5:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 5:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TER
Neutral
high confidence
Mentioned
$TER
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TERNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale of 4,000 shares at $356.31 on 2026-07-15, totaling $1,425,240, under a pre-arranged 10b5-1 plan.

02

Market read

Insider-sale filings can affect short-term sentiment, but 10b5-1 plans generally make the signal weaker.

03

What to watch

The article provides no context on total insider holdings beyond post-transaction shares, and no buy/sell pattern history is included.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-07-16 for a sale executed on 2026-07-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Teradyne, Inc.

Company-level read

Ticker impact

$TERNeutralHigh confidence
Context

Teradyne CEO and President Smith Gregory Stephen sold 4,000 shares in an open-market transaction worth $1.43M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; traders may treat as non-informational given the stated 10b5-1 pre-arranged plan.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces signaling value versus discretionary sales.

Market effects

Minimal, as the disclosure does not change Teradyne’s operating outlook or sector fundamentals.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with valuation or liquidity needs, so some traders may watch for follow-on sales.

Key entities

  • TERADYNE, INC

    US-listed company whose CEO filed the Form 4 insider sale disclosure.

  • Smith Gregory Stephen

    President and CEO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FORMMedAI 8/10

FormFactor, Entegris, Penguin Solutions, Teradyne, and Marvell Technology Stocks Trade Up, What You Need To Know

Several semiconductor stocks rose after the August jobs report, which showed 162,000 nonfarm payroll jobs added, beating estimates. Despite initial expectations of a rate hike, traders rotated back into the chip sector. FormFactor (FORM) +5.3%, Entegris (ENTG) +5.6%, Penguin Solutions (PENG) +5.1%, Teradyne (TER) +4.8%, and Marvell Technology (MRVL) +6.2%. Marvell reported Q2 revenue of $2.74B, up 36.5% YoY, with strong Data Center demand. Management guided Q3 revenue at $3.15B, but revenue from

$TERMed

Teradyne Stock Plunges 15% in a Month: Should You Buy the Dip?

Teradyne (TER) shares fell 15.4% in a month, underperforming peers and sector. Challenges include customer concentration and muted demand, but AI-driven data center growth and strong Q3 guidance offset this. TER expects $1.20-$1.30B revenue and $1.85-$2.15 EPS for Q3 2026, up significantly YoY. The stock trades at a premium with a forward P/S of 9.35X.

$TERHigh

Why is Teradyne stock sliding today?

Teradyne (TER) stock fell 3.9% after Baird downgraded it to Neutral with a $420 price target, citing stretched valuation and concerns over AI and hyperscaler spending sustainability. The firm argues GPU testing catalyst is priced in and next growth drivers are too distant. TER's decline contrasts with broader market gains, highlighting company-specific pressures.

$METAMed

Stocks making the biggest moves midday: Meta, Amylyx, Baidu, Klarna, Coherent, Sandisk & more

Amylyx Pharmaceuticals shares rose 53% after its avexitide treatment met trial endpoints. Meta Platforms fell 3% amid a lawsuit. Carvana dropped 3% after director stock sales. UGI Corporation surged 12% on a $9B KKR bid report. AI-related stocks declined. Klarna fell 21% on weak guidance. Baidu dropped 12% on earnings miss. Home Depot rose slightly on earnings beat. Fabrinet fell 20% on margin concerns. Memory stocks declined. Duolingo rose 7% on an upgrade.